Identifying immune profiles in acute pancreatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MoSAIC study is a prospective, observational initiative aimed at developing an early prediction tool for severe acute pancreatitis (SAP) by analyzing immune responses. It seeks to validate a multi-cytokine panel for predicting SAP and to identify immune cells associated with cytokine signatures during early acute pancreatitis. Participants will provide blood samples and complete surveys within 36 hours of hospital admission, with follow-ups at 48 hours and on hospital day 7. Data on clinical outcomes, medical history, and disease severity will be collected to enhance understanding of immune pathways in acute pancreatitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-75 years at the time of enrollment
2. Diagnosis of acute pancreatitis (AP) according to the revised Atlanta criteria (see definition below)
3. Participant is approached by the research team within 36 hours of presentation to the hospital
4. Participant fully understands and agrees to participate in all aspects of the study, including providing informed consent, completion of interviews and data forms, and collection of biospecimens

Acute pancreatitis is defined/diagnosed using the revised Atlanta criteria, which requires the presence of at least two of the following criteria:

i. Upper abdominal pain ii. Elevation of serum amylase or lipase level to \>/=3 times the upper limit of normal iii. Features of AP on cross-sectional imaging.

Exclusion Criteria:

1. Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also study definitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP):

   i. Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular) ii. Intraductal filling defects suggestive of calcifications on MRI and/or MRCP iii. Non-contrast imaging is acceptable for the assessment of definite CP, but calcifications noted by endoscopic ultrasound only (and not correlated with CT) are not considered definite CP. Patients with autoimmune pancreatitis, but no evidence of calcifications, may still be enrolled, assuming they satisfy inclusion criteria for 'diagnosis of AP'
2. Potential participants with post-ERCP AP who are expected to be hospitalized for less than 48 hours.
3. Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis.
4. Confirmed or suspected cystic tumor associated with main pancreatic duct dilation or believed to be the cause of AP (in the site-PI's judgment).
5. Prior pancreatic surgery, including, but not limited to distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, and Frey procedure.
6. Severe systemic illness that in the judgment of the investigative team will confound outcome assessments and immunological outcomes or pose additional risk for harm, including the history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with eGFR \<30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \<12 months.
7. Known pregnancy at the time of enrollment.
8. Incarceration.
9. Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study.

Where it's running

• The Ohio State University
  Columbus, Ohio, United States Recruiting
• University of Southern California
  Los Angeles, California, United States Not yet recruiting
• University of Illinois Chicago
  Chicago, Illinois, United States Not yet recruiting
• University of Pittsburgh
  Pittsburgh, Pennsylvania, United States Not yet recruiting
• Benaroya Research Institute
  Seattle, Washington, United States Not yet recruiting

Study contacts

• Study coordinator: Zoe Krebs, BA
• Email: zoe.krebs@osumc.edu
• Phone: 614-685-3619

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Local complications of acute pancreatitis and postoperative pancreatic fistula: what happens in real life

  This multicenter registry tests how local pancreatic complications are managed in routine care and what outcomes look like over 180 days for adults.

  Recruiting at 12 sites Tokyo University · Ōtsu, Shiga and 11 other locations · NCT07862088

• SGC001 is being tested to help predicted severe acute pancreatitis

  Researchers are testing SGC001 vs placebo in adults with predicted severe acute pancreatitis to see if it is safe and tolerable and to get a sense of any early effects.

  Recruiting Phase 2 Beijing Sungen Biomedical Technology Co., Ltd · Chengdu and 14 other locations · NCT07803965

• Fecal microbiota transplant to prevent infections after late-phase severe acute pancreatitis

  This trial will test whether giving healthy donor gut bacteria (fecal microbiota transplantation) through a feeding tube in the late phase of moderately severe or severe acute pancreatitis can prevent infectious complications.

  Recruiting Changhai Hospital · Fuzhou, Fujian and 11 other locations · NCT07464392

• How often splanchnic vein clots occur in acute pancreatitis and whether they relate to disease severity

  This project will see if people with acute pancreatitis develop blood clots in the splenic, portal, or superior mesenteric veins and whether those clots are linked to more severe illness.

  Recruiting Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07322978

• Fecal microbiota transplant for people with moderate to severe acute pancreatitis

  This trial will test whether a fecal microbiota transplant (FMT) can reduce late complications in adults with moderate to severe acute pancreatitis.

  Recruiting at 2 sites Changhai Hospital · Shanghai, Shanghai Municipality and 1 other locations · NCT07153809

• Blood markers to detect infected pancreatic necrosis

  We will test whether specific blood markers can help predict or diagnose infected pancreatic necrosis in adults with necrotizing pancreatitis.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT06899087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.